Beleave Inc. (CSE:BE; OTCQX:BLEVF) (“Beleave” or the “Company”) due to an influx of inquiries from patients would like to provide guidance on the previously released Veterans Affairs Canada’s Medical Cannabis Program administered by Medavie Blue Cross.
The program is available to patients though Veterans Affairs Canada only. For prospective patients, please refer to ACMPR guidelines for more information.
For additional patient information please contact Beleave’s Director of Customer Service Anne Whelan either via email at email@example.com or by phone at 905-517-7306
Alternatively, to stay informed please join the company mailing list at www.beleave.com.
Beleave Inc. is a biotech company and Beleave’s wholly-owned subsidiary Beleave Kannabis Corp. (formerly First Access Medical Inc.) is a licensed producer pursuant to the ACMPR. Beleave’s purpose-built facility is located in Hamilton, Ontario.
This news release contains “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”). The use of any of the words “plan”, “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and other similar words, or statements that certain events or conditions “may” or “will” occur are intended to identify forward-looking information. These statements are only predictions. Although the Company believes that the expectations and assumptions on which the forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Since forward-looking information addresses future events and conditions, by its very nature it involves inherent risks and uncertainties. This information speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com.
SOURCE Beleave Continue Reading